Literature DB >> 11313876

Coexpression of hepatocyte growth factor-Met: an early step in ovarian carcinogenesis?

A S Wong1, S L Pelech, M M Woo, G Yim, B Rosen, T Ehlen, P C Leung, N Auersperg.   

Abstract

Since autocrine regulation of HGF-Met is implicated in many forms of human cancer, we investigated whether the predisposition to develop ovarian cancer in women with hereditary ovarian cancer syndromes involves changes in the expression of HGF-Met by the tissue of origin of epithelial ovarian cancers, the ovarian surface epithelium (OSE). We compared cultures of normal OSE from women with (FH-OSE) (n=20) and with no (NFH-OSE) (n=48) family histories of ovarian cancer, SV40 Tag immortalized OSE lines (IOSE, n=5) and ovarian cancer cell lines (n=3). Cultures derived from 21/22 women with NFH-OSE and 13/13 women with FH-OSE expressed Met mRNA initially. After two to three passages, Met was downregulated in 37% of NFH-OSE cultures but persisted in 100% of FH-OSE cultures and ovarian cancer lines, like other epithelial differentiation markers that are stabilized in FH-OSE and neoplasia. HGF and Met mRNA were concomitantly expressed by NFH-OSE from only three of 32 women but in FH-OSE from eight of 13 women, and also in five of five IOSE and two of three ovarian cancer lines. Conditioned media from FH-OSE, but not NFH-OSE, contained immunoreactive HGF and induced cohort migration which was inhibited by neutralizing HGF antibody. Several signaling molecules of the PI3K pathway, including Akt2 and p70 S6K, were constitutively activated in FH-OSE from six of six women but in NFH-OSE from only four of eight women. Exogenous HGF was mitogenic in OSE, and that effect was regulated through the MAP kinase (ERK1/ERK2) and FRAP/p70 S6K pathways. The proliferative response to HGF was greater in NFH-OSE than in FH-OSE cultures. The results show that FH-OSE cultures differ from NFH-OSE by increased stability of Met expression and by HGF secretion. Constitutive phosphorylation of kinases and a diminished growth response to HGF suggest the presence of autocrine regulation in FH-OSE. In analogy with other cell types where an autocrine HGF-Met loop has been implicated in tumorigenic transformation, this change in FH-OSE may play a role in the enhanced susceptibility to ovarian carcinogenesis in women with hereditary ovarian cancer syndromes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11313876     DOI: 10.1038/sj.onc.1204253

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  27 in total

1.  MET-dependent cancer invasion may be preprogrammed by early alterations of p53-regulated feedforward loop and triggered by stromal cell-derived HGF.

Authors:  Chang-Il Hwang; Jinhyang Choi; Zongxiang Zhou; Andrea Flesken-Nikitin; Alexander Tarakhovsky; Alexander Yu Nikitin
Journal:  Cell Cycle       Date:  2011-11-15       Impact factor: 4.534

2.  Differentiation and growth potential of human ovarian surface epithelial cells expressing temperature-sensitive SV40 T antigen.

Authors:  E H Leung; P C Leung; N Auersperg
Journal:  In Vitro Cell Dev Biol Anim       Date:  2001-09       Impact factor: 2.416

3.  Novel MicroRNAs regulating proliferation and apoptosis in uterine papillary serous carcinomas.

Authors:  Claire M Mach; Jong Kim; Benjamin Soibam; Chad J Creighton; Shannon M Hawkins; Israel Zighelboim; Paul Goodfellow; Preethi H Gunaratne; Kunle Odunsi; Philip A Salem; Matthew L Anderson
Journal:  Cancer Lett       Date:  2013-02-26       Impact factor: 8.679

Review 4.  Biology of MET: a double life between normal tissue repair and tumor progression.

Authors:  Iacopo Petrini
Journal:  Ann Transl Med       Date:  2015-04

5.  High incidence of ErbB3, ErbB4, and MET expression in ovarian cancer.

Authors:  Suzy Davies; Anna Holmes; Lesley Lomo; Mara P Steinkamp; Huining Kang; Carolyn Y Muller; Bridget S Wilson
Journal:  Int J Gynecol Pathol       Date:  2014-07       Impact factor: 2.762

Review 6.  The Therapeutic Potential of Targeting the HGF/cMET Axis in Ovarian Cancer.

Authors:  Kim Moran-Jones
Journal:  Mol Diagn Ther       Date:  2016-06       Impact factor: 4.074

7.  A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.

Authors:  Lainie P Martin; Michael Sill; Mark S Shahin; Matthew Powell; Paul DiSilvestro; Lisa M Landrum; Stephanie L Gaillard; Michael J Goodheart; James Hoffman; Russell J Schilder
Journal:  Gynecol Oncol       Date:  2013-12-18       Impact factor: 5.482

8.  Differential effects of cellular fibronectin and plasma fibronectin on ovarian cancer cell adhesion, migration, and invasion.

Authors:  Ladan Zand; Feng Qiang; Calvin D Roskelley; Peter C K Leung; Nelly Auersperg
Journal:  In Vitro Cell Dev Biol Anim       Date:  2003 Mar-Apr       Impact factor: 2.416

9.  Expression and mutational analysis of MET in human solid cancers.

Authors:  Patrick C Ma; Maria S Tretiakova; Alexander C MacKinnon; Nithya Ramnath; Candace Johnson; Sascha Dietrich; Tanguy Seiwert; James G Christensen; Ramasamy Jagadeeswaran; Thomas Krausz; Everett E Vokes; Aliya N Husain; Ravi Salgia
Journal:  Genes Chromosomes Cancer       Date:  2008-12       Impact factor: 5.006

Review 10.  Early events in ovarian oncogenesis.

Authors:  Dusica Cvetkovic
Journal:  Reprod Biol Endocrinol       Date:  2003-10-07       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.